Corentec: Q1 2026 Consolidated Sales 245.8B, Operating Profit 8.86B, Debt Ratio Improves to 77.2%

Q1 2026 consolidated sales: 245.7B KRW (+8.6% YoY); operating profit: 8.86B KRW (down from 10.43B last year); net profit attributable to controlling interests: 1.28B KRW (up from 1.05B in continuing operations last year).
Debt ratio: 77.2% (improved from 92.8% at year-end 2025); total equity 90.56B KRW, total liabilities 69.92B KRW.
Credit rating: BBB+ (Nice D&B, 2026.04.27).
No share buyback, cancellation, or dividends.
Outstanding convertible bond (10th series, 4.8B KRW, issued 2025.12.29, maturity 2027.06.29, conversion price 6,176 won) and redeemable convertible preferred shares (621,670 shares, issued 2019.08.05, conversion price 5,630 won).
Core products: hip implants (37.4% of revenue), knee implants (47.7%); continued FDA approvals.